ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2025
Belatacept as an alternative immunosuppressive agent for bone marrow-sparing in idiopathic pulmonary fibrosis lung transplant recipients with short telomeres.
Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Belatacept in Solid Organ Transplantation: Current Kidney Applications, Future Perspectives in Other Organs, and Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
As we have previously shown, idiopathic pulmonary fibrosis lung transplant recipients (IPF-LTRs) with short-telomere length are prone to develop significant cytopenias and poor tolerance to cell-cycle inhibitors, specifically mycophenolate mofetil (MMF), post transplant. We investigated the use of belatacept as an alternative immunosuppressive agent in a prospective, open-label cohort of 9 ST-IPF-LTRs at our institution. These patients were either challenged with MMF (majority) or immediately started on belatacept post transplant with the goal to bridge to everolimus, an mammalian target of rapamycin inhibitor that is commonly used post transplant. We describe outcomes in the first-year post transplant, including the incidence of acute cellular rejection, Epstein-Barr virus viremia, and 1 case of post-transplant lymphoproliferative disorder (PTLD) at 13 months. The use of belatacept postlung transplant may be an acceptable short-term alternative therapy to cell-cycle inhibitors in ST-IPF-LTRs with cytopenias but may lead to a higher risk of Epstein-Barr Virus viremia and PTLD when belatacept is used long term in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.